Karthikeyan Murugesan
Overview
Explore the profile of Karthikeyan Murugesan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
R P, M Basalingappa K, D S, K R A, K G, J S, et al.
Luminescence
. 2024 Sep;
39(9):e4898.
PMID: 39323008
Cyanobacteria are resilient microorganisms and thrive in environments exposed to UV radiation, ranging from ocean surfaces to scorching hot springs and dry expanses. 'Cyanobacterial Resilience' refers to their ability to...
2.
Murugesan K, Kumar M, Kaniraja G, Ananthappan P, Vasantha V, Karunakaran C
Anal Biochem
. 2024 Sep;
696:115676.
PMID: 39307447
Norepinephrine (NE) is the primary catecholamine (CA) of interest in the medical field, as it plays a key role in regulating the hormonal and neurological systems. Some NE concentration dysfunction...
3.
Stein L, Murugesan K, Reeser J, Risch Z, Wing M, Paruchuri A, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):207.
PMID: 39289482
Genomic alterations in fibroblast growth factor receptor (FGFR) genes are present in a small number of metastatic pancreatic ductal adenocarcinomas (PDAC) and may represent an emerging subgroup of patients likely...
4.
Moffat G, Hu Z, Meric-Bernstam F, Kong E, Pavlick D, Ross J, et al.
JAMA Netw Open
. 2024 May;
7(5):e249840.
PMID: 38709532
Importance: Biliary tract cancers (BTCs) contain several actionable molecular alterations, including FGFR2, IDH1, ERBB2 (formerly HER2), and KRAS. KRAS allelic variants are found in 20% to 30% of BTCs, and...
5.
Makawita S, Lee S, Kong E, Kwong L, Abouelfetouh Z, De Armas A, et al.
JCO Precis Oncol
. 2024 Mar;
8:e2300544.
PMID: 38547421
Purpose: Isocitrate dehydrogenase ()/ genomic alterations (GA) occur in 20% of intrahepatic cholangiocarcinoma (iCCA); however, the immunogenomic landscape of mutated iCCA is largely unknown. Methods: Comprehensive genomic profiling (CGP) was...
6.
Vogel A, Murugesan K, Kendre G, Quintanilha J, Ross J, Brummer T, et al.
JCO Precis Oncol
. 2024 Feb;
8:e2300411.
PMID: 38394466
Purpose: Recent studies have provided evidence for a predictive value of genetic alterations (GAs) as biomarkers for targeted therapies in microsatellite-stable (MSS) colorectal cancer (CRC). These data have the potential...
7.
Roy B, Murugesan K, Mathanmohun M, Sathian B
Nepal J Epidemiol
. 2024 Feb;
13(4):1294-1297.
PMID: 38299042
Nanoparticles (NPs) are small particles with a surface area ranging from 1 to 100 nm in diameter that are rampantly used in different fields, e.g., medicine, engineering, and others. Because...
8.
Russo A, Lee J, Pasquina L, Del Re M, Dilks H, Murugesan K, et al.
JCO Precis Oncol
. 2024 Jan;
8:e2300535.
PMID: 38295321
Purpose: Studies have investigated the early use of liquid biopsy (LBx) during the diagnostic workup of patients presenting with clinical evidence of advanced lung cancer, but real-world adoption and impact...
9.
Wang D, Elenbaas B, Murugesan K, Shah K, Montesion M, Gounaris I, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):103.
PMID: 37821580
The DNA damage response (DDR) pathway regulates DNA repair and cell survival, and inactivating mutations in DDR genes can increase tumour mutational burden (TMB), a predictive biomarker of treatment benefit...
10.
Moore J, Chen K, Madison R, Newberg J, Fleischmann Z, Wang S, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2300093.
PMID: 37769224
Purpose: Copy-number (CN) features reveal the molecular state of cancers and may have predictive and prognostic value in the treatment of cancer. We sought to apply published CN analysis methods...